BBIO Q3 FY26 earnings call: key takeaways

• Atrubi's third-quarter revenue of $353.2 million exceeded the $295.75 million consensus estimate. (5:59)
• EPS of -$0.42 beat the -$0.60 consensus estimate. (5:59)
• The company reported strong growth in Atrubi, with a focus on first-line new starts and real-world evidence supporting its market position. (5:59)

Results vs expectations

EPS basis: GAAP diluted EPS, SEC 10-Q

The stock moved +6.0% over the report window (S&P 500 ETF -1.8%). Earnings history

What changed since last quarter

• The company raised its peak year sales assumption for Atrubi to $4 billion, citing strong growth and real-world evidence. (4:29)
• The PDUFA date for BBP418 remains November 27, 2026, with no advisory committee planned. (13:29)
• The company emphasized the importance of expanding the prescriber base to target the long tail of physicians. (37:29)

What analysts pressed on

• Whether the 340B plan changes could impact Atrubi's refills and new accounts. (35:23)
• Concerns about the potential impact of a citizen's petition on infagratinib's review timeline and label. (44:25)
• Questions about the commercial implications of the citizen's petition and how the company is addressing physician perceptions. (44:57)

In their words

• The drug is manufactured and ready to go and channel. (15:29)
• We are a company with three launches in the next seven months. (20:59)
• We have the best team in the industry. (35:58)